Reuters: Global Markets: Supernus epilepsy drug gets tentative FDA nod

Reuters: Global Markets Reuters.com is your source for breaking news, business, financial and investing news, including personal finance and stocks. Reuters is the leading global provider of news, financial information and technology solutions to the world's media, financial institutions, businesses and individuals. // via fulltextrssfeed.com

Supernus epilepsy drug gets tentative FDA nod Jun 26th 2012, 13:23 Tue Jun 26, 2012 9:23am EDT (Reuters) - Supernus Pharmaceuticals Inc said the U.S. health regulator granted a tentative approval to its epilepsy treatment Trokendi XR, sending its shares up 38 percent before the bell. The company said the U.S. Food and Drug Administration completed a review of Trokendi, an extended release version of Johnson & Johnson's widely-used epilepsy drug Topamax, and did not seek any additional clinical trials. Topamax is off patent protection and is available generically. Supernus said the final approval of its drug depended on resolving a marketing exclusivity issue raised by the FDA regarding a specific pediatric population. Shares of Supernus were trading at $7.75 in premarket trade. They closed at $5.71 on Monday on the Nasdaq.

You are receiving this email because you subscribed to this feed at blogtrottr.com. If you no longer wish to receive these emails, you can unsubscribe from this feed, or manage all your subscriptions